SGRY Surgery Partners, Inc.
Services-General Medical & Surgical Hospitals, NEC · Nasdaq · SEC CIK 1638833 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.2%
TTM net income YoY49.2%
TTM EPS YoY50.7%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin10.8%
Net margin-2.6%
FCF margin6.0%
EBITDA margin16.1%
Returns
ROE-5.1%
ROA-1.2%
ROIC (approx.)6.1%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets53.8%
Debt / equity1.84x
Current ratio2.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-3.19x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $815.30M | $848.90M | $810.90M | $885.00M | $821.50M | $826.20M | $776.00M | $864.40M |
| SG&A expense | $40.60M | $36.30M | $39.30M | $23.70M | $22.40M | $36.10M | $36.00M | $36.00M |
| Operating income | $85.60M | $102.10M | $65.80M | $110.20M | $105.70M | $111.70M | $61.90M | $127.10M |
| Pretax income | $17.70M | $32.30M | -$3.30M | $42.60M | $30.80M | $43.80M | -$300,000 | $74.20M |
| Income tax | $3.60M | $2.60M | -$1.20M | $13.60M | $5.50M | -$1.10M | $0 | $120.80M |
| Net income | -$21.10M | -$15.00M | -$35.90M | -$15.00M | -$22.70M | -$2.50M | -$37.70M | -$108.50M |
| EBITDA | $125.20M | $141.40M | $104.30M | $170.10M | $145.20M | $152.00M | $98.20M | $161.00M |
| EPS (basic) | -0.16 | -0.12 | -0.28 | — | -0.18 | -0.02 | -0.30 | — |
| EPS (diluted) | -0.16 | -0.12 | -0.28 | — | -0.18 | -0.02 | -0.30 | — |
| Weighted avg. shares (diluted) | 128.87M | 128.82M | 128.37M | — | 127.21M | 126.98M | 126.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $354.50M | $216.70M | $182.30M | $239.90M | $203.40M | $250.10M | $229.30M | $269.50M |
| Receivables | $468.10M | $616.60M | $603.40M | $602.20M | $579.30M | $563.10M | $570.60M | $579.10M |
| Inventory | $77.50M | $98.80M | $100.50M | $96.60M | $92.30M | $87.30M | $88.10M | $88.40M |
| Current assets | $1.08B | $1.13B | $1.08B | $1.15B | $1.10B | $1.11B | $1.07B | $1.12B |
| PP&E, net | $840.60M | $1.12B | $1.13B | $1.15B | $1.16B | $1.18B | $1.15B | $1.09B |
| Goodwill | $4.61B | $5.20B | $5.21B | $5.19B | $5.09B | $5.10B | $5.13B | $5.07B |
| Intangibles | — | — | — | $41.00M | — | — | — | $45.70M |
| Total assets | $7.05B | $8.05B | $8.04B | $8.12B | $7.95B | $7.95B | $7.95B | $7.89B |
| Current liabilities | $498.60M | $578.50M | $581.70M | $615.50M | $586.00M | $573.30M | $569.40M | $624.40M |
| Short-term debt | $56.50M | $102.90M | $100.40M | $99.30M | $103.00M | $110.00M | $103.90M | $101.40M |
| Long-term debt | $3.00B | $3.65B | $3.61B | $3.60B | $3.46B | $3.47B | $3.45B | $3.27B |
| Total debt | $3.06B | $3.75B | $3.71B | $3.70B | $3.56B | $3.58B | $3.55B | $3.37B |
| Total liabilities | $3.79B | $4.58B | $4.56B | $4.59B | $4.39B | $4.38B | $4.36B | $4.25B |
| Shareholders' equity | $1.66B | $1.67B | $1.69B | $1.71B | $1.73B | $1.75B | $1.74B | $1.79B |
| Net debt | $2.70B | $3.53B | $3.53B | $3.46B | $3.36B | $3.33B | $3.32B | $3.10B |
| Shares outstanding | 130.86M | 130.89M | 130.80M | 129.32M | 129.02M | 128.21M | 128.19M | 127.11M |
| Cash flow statement | ||||||||
| Operating cash flow | $103.50M | $59.30M | $11.70M | $103.40M | $83.60M | $81.30M | $6.00M | $111.40M |
| Capital expenditure | $24.50M | $21.80M | $16.00M | $12.80M | $19.80M | $23.40M | $22.70M | $22.30M |
| Free cash flow | $79.00M | $37.50M | -$4.30M | $90.60M | $63.80M | $57.90M | -$16.70M | $89.10M |
| Investing cash flow | $468.00M | -$19.80M | -$13.40M | -$126.10M | -$46.20M | $2.10M | -$76.40M | -$111.70M |
| Financing cash flow | -$433.70M | -$5.10M | -$55.90M | $59.20M | -$84.10M | -$62.60M | $30.20M | $48.00M |
| Depreciation & amortization | $39.60M | $39.30M | $38.50M | $59.90M | $39.50M | $40.30M | $36.30M | $33.90M |
| Stock-based compensation | $6.00M | $3.80M | $5.80M | -$2.20M | $2.60M | $6.80M | $7.60M | $6.20M |
Free plan shows the latest 8 periods; Pro shows all 50 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.